Identification, Characterization and Immunogenicity of an O-Antigen Capsular Polysaccharide of Francisella tularensis by Apicella, Michael A. et al.
Identification, Characterization and Immunogenicity of
an O-Antigen Capsular Polysaccharide of Francisella
tularensis
Michael A. Apicella
1*
., Deborah M. B. Post
2., Andrew C. Fowler
1, Bradley D. Jones
1, Jed A. Rasmussen
1,
Jason R. Hunt
1, Sayaka Imagawa
3, Biswa Choudhury
3, Thomas J. Inzana
4, Tamara M. Maier
5, Dara W.
Frank
5, Thomas C. Zahrt
5, Kathryn Chaloner
6, Michael P. Jennings
7, Molly K. McLendon
1, Bradford W.
Gibson
2
1Department of Microbiology, University of Iowa, Iowa City, Iowa, United States of America, 2Buck Institute for Age Research, Novato, California, United States of
America, 3Glycotechnology Core Resource, University of California San Diego, San Diego, California, United States of America, 4Virginia-Maryland Regional College of
Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America, 5Center for Biopreparedness and Infectious
Diseases, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America, 6Department of Biostatistics, College of Public Health, The University of Iowa,
Iowa City, Iowa, United States of America, 7Institute for Glycomics, Griffith University, Gold Coast, Australia
Abstract
Capsular polysaccharides are important factors in bacterial pathogenesis and have been the target of a number of
successful vaccines. Francisella tularensis has been considered to express a capsular antigen but none has been isolated or
characterized. We have developed a monoclonal antibody, 11B7, which recognizes the capsular polysaccharide of F.
tularensis migrating on Western blot as a diffuse band between 100 kDa and 250 kDa. The capsule stains poorly on SDS-
PAGE with silver stain but can be visualized using ProQ Emerald glycoprotein stain. The capsule appears to be highly
conserved among strains of F. tularensis as antibody 11B7 bound to the capsule of 14 of 14 F. tularensis type A and B strains
on Western blot. The capsular material can be isolated essentially free of LPS, is phenol and proteinase K resistant, ethanol
precipitable and does not dissociate in sodium dodecyl sulfate. Immunoelectron microscopy with colloidal gold
demonstrates 11B7 circumferentially staining the surface of F. tularensis which is typical of a polysaccharide capsule. Mass
spectrometry, compositional analysis and NMR indicate that the capsule is composed of a polymer of the tetrasaccharide
repeat, 4)-a-D-GalNAcAN-(1-.4)-a-D-GalNAcAN-(1-.3)-b-D-QuiNAc-(1-.2)-b-D-Qui4NFm-(1-, which is identical to the
previously described F. tularensis O-antigen subunit. This indicates that the F. tularensis capsule can be classified as an
O-antigen capsular polysaccharide. Our studies indicate that F. tularensis O-antigen glycosyltransferase mutants do not
make a capsule. An F. tularensis acyltransferase and an O-antigen polymerase mutant had no evidence of an O-antigen but
expressed a capsular antigen. Passive immunization of BALB/c mice with 75 mg of 11B7 protected against a 150 fold lethal
challenge of F. tularensis LVS. Active immunization of BALB/c mice with 10 mg of capsule showed a similar level of
protection. These studies demonstrate that F. tularensis produces an O-antigen capsule that may be the basis of a future
vaccine.
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Introduction
Francisella tularensis is a gram-negative, aerobic, facultative intra-
cellular bacterium and is the etiological agent of tularemia. The
organism was first described by McCoy and Corbin in 1911 in
Tulare County California [1]. F. tularensis is found throughout the
Northern hemisphere. Infection with F. tularensis can occur by
inhalation, insect bite, subcutaneous inoculation through a break
in the skin, ingestion of contaminated meat or water, or by animal
bite [2]. F. tularensis is one of the most infectious bacterial
organisms known and as few as 10 organisms can cause disease in
humans by inoculation or inhalation [3,4]. In the United States,
the majority of endemic disease occurs in hunters, laboratory
personnel and children in rural areas. The highest incidence of
disease has occurred in the USA over the past decade in Missouri
and Arkansas [5]. Children from age three to ten and adults over
50 have the greatest incidences of disease [5]. Several forms of the
disease can occur that depend on the route of infection, dose of
bacteria and virulence of the infecting organism, including:
ulceroglandular, glandular, oculoglandular, oropharyngeal and
pneumonic. Infection with F. tularensis is marked with abrupt onset
of symptoms, including fever, headache and body aches [2]. Left
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11060untreated, infection is associated with high morbidity and
mortality.
F. tularensis is classified as a Category A biological agent by the
Strategic Planning Work Group of the Centers for Disease Control
and Prevention as most likely to pose a potential national security
risk [5,6]. F. tularensis has the potential to be an efficient agent of
biological warfare because it is highly infectious [6]. In addition,
the bacterium is stable over a variety of environmental conditions,
is easily dispersed as an aerosol, large quantities of the bacterium
can be easily manufactured, the general population is susceptible
to infection and infections lead to high morbidity and mortality
[7]. It is estimated that intentional airborne release of F. tularensis
into a metropolitan area of a major city would result in major
morbidity, mortality and financial loss [7].
Previously, a live attenuated F. tularensis vaccine was available to
at-risk personnel; however, it did not provide complete protection
against all forms of the disease. Vaccinated human volunteers were
protected during aerosol infection from the most dangerous
typhoidal form of infection, but the incidence of the ulceroglan-
dular form of the disease was not affected; instead, vaccination
lessened the severity of the infection [8]. Development of a new
vaccine is necessary because of limitations with the current
vaccine. These include difficulty in standardizing the vaccine
because it is administered via scarification and phenotypic
instability of the vaccine strain. Little is known about the necessary
protective antigens or what arm of the immune response should be
targeted with the vaccine. Recent reports indicate that the vaccine
strain may be able to reacquire some virulence characteristics on
passage [9]. Therefore, an intensified search is underway to
develop a defined subunit vaccine comprised of Francisella cell
surface components such as protein antigens, lipopolysaccharide
(LPS) [10] and/or capsule, or a live vaccine with specific genetic
modifications which preclude reversion to virulence.
Capsular antigens have been proven to be the basis for effective
vaccines for Gram-negative and Gram-positive human pathogens
[11,12]. F. tularensis has been considered to be encapsulated for
over 40 years based on smooth to rough colony phenotype
transition and evidence of the presence of conserved polysaccha-
ride structures in the organism [13]. Currently, little is known
about the chemical structure or antigenic nature of the capsular
antigen of F. tularensis. A purified capsular preparation has never
been described and most published reports dealing with capsule
depended on identifying ‘‘rough’’ colonies which were considered
unencapsulated [14,15].
Using a crude ‘‘capsular’’ extract from F. tularensis subsp.
tularensis SCHU S4 as prepared by the method of Hood as an
immunogen [16], we developed a bank of monoclonal antibodies
and evaluated each for binding to antigens with the characteristics
of a typical polysaccharide capsule that help distinguish it from the
LPS. The characteristics include being protease and phenol
resistant, ethanol precipitable and having a high molecular weight
(.100 kDa). Two of these monoclonal antibodies bound a high
mass capsule-like structure on Western blot that matched these
characteristics. Using one of these antibodies as a probe, we were
able to purify this capsular material, free of other bacterial
components including LPS. Physiochemical analysis of the antigen
indicated that it contains a tetrasaccharide repeat, 2-acetamido-
2,6-dideoxy-O-D-glucose (O-QuiNAc), 4,6-dideoxy-4-formamido-
D-glucose (O-Qui4NFm), and 2-acetamido-2-deoxy-O-D-galac-
turonamide (O-GalNAcAN) of similar, if not identical, structure
and composition to the LPS O-antigen. Compositional analysis
and mass spectrometry studies did not identify Kdo or lipid A as a
component of the capsular antigen. Passive immunization with this
monoclonal antibody and active immunization of BALB/c mice
with the capsule was protective against a challenge of 150-fold the
LD50 of F. tularensis LVS. Immunization of these mice with the
capsule resulted in generation of antibodies to the capsule
preparation and not the O-antigen subunits of the LPS
demonstrating a unique epitopic structure to the capsule. These
results indicate that the F. tularensis capsule produces an O-antigen
capsule which may have the potential to be a protective
immunogen against F. tularensis infection.
Results
Development and characterization of the F. tularensis
anti-capsular monoclonal antibody
In order to determine if F. tularensis SCHU S4 produced a
capsular antigen and to develop a probe for it, we elected to make
monoclonal antibodies (MAb) to a high salt extract of F. tularensis
subsp. tularensis SCHU S4 prepared according to the method of
Hood [16]. This resulted in the identification of antibody 11B7
which recognized a structure with the characteristics of a
carbohydrate capsular antigen, i.e., high mass, diffusely migrating,
and resistant to proteolytic enzymes and phenol. As can be seen in
Figure 1, Western blot analysis indicated that MAb 11B7 bound to
a structure between 100 kDa and 250 kDa. Subsequent studies
demonstrated that this structure had the characteristics of a
polysaccharide capsule. Figure 1 also demonstrates the conserved
nature of the putative capsule as five distinct strains of F. tularensis
obtained as glutaraldehyde-fixed organisms and F. tularensis subsp.
Figure 1. Figure 1 shows a Western blot of six F. tularensis
strains using MAb 11B7. This antibody binds to capsule from lysates
of five F. tularensis strains from the Oregon State Health lab (lanes 1-5)
and F. tularensis subsp holarctica 1547 (lane 6).
doi:10.1371/journal.pone.0011060.g001
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that the capsular material was firmly associated with the intact
bacteria as only minimal amounts of capsule could be detected in
broth culture supernates cleared of organisms at 4, 8 and 24 hours
(Figure S1). Subsequent studies indicated that a similar structure
could be identified in 15 F. tularensis type A and type B strains from
a wide geographic distribution in North America (Table 1). We
performed immunoelectron microscopy using ‘‘whole mount’’
samples and cryo-immunoelectron microscopy on strains F.
tularensis SCHU S4, 1547 and LVS using MAb 11B7. A
representative stained images of each is shown in Figure 2A and
2C. This demonstrates the presence of circumferential labeling of
the organism by this antibody confirming the surface location of
the antigen. The secondary antibody controls for both studies
show no labeling (Figure 2B and 2D).
Characterization of the capsule from Francisella tularensis
Using the NaCl extraction method described by Hood [16],
followed by proteinase digestion, phenol extraction, Triton X-114
treatment and Sephacryl S500 chromatography, we have been
able to isolate the capsule away from contaminating LPS.
Figure 3A shows a ProQ Emerald glycostain of fractions from a
Sephacryl S-500HR chromatography of a F. tularensis SCHU S4
crude capsule prep before treatment with Triton X114. The buffer
used contained 100 mM NaCl, 10 mM EDTA, 10 mM Tris, 2%
SDS pH 7.4 and the chromatography was performed at 37uC.
The column void volume was 11 ml (tube 11) and the bed volume
was 30 ml. The capsule eluted between 12 and 16 ml and the LPS
eluted at 21 ml. Figure 3B shows an immunodot assay of each
fraction using MAb 11B7. The MAb 11B7 reactivity to capsule
occurs in tubes 12 through 15. Using MAb 11B7 to track the
capsule, we have been able to isolate highly purified capsule in
milligram quantities from F. tularensis SCHU S4, F. tularensis LVS
and F. tularensis subsp. holarctica strain 1547. Figure 4 shows
comparative staining of the capsule and LPS with silver stain,
ProQ Emerald glycostain, MAb 11B7 and the anti-LPS MAb
FB11. As can be seen, the silver stain does not readily show the
capsule which is visible in the ProQ Emerald stain. Figure 4 Panel
C shows that MAb 11B7 reacts most intensely with lane 2,
indicating that this is where the majority of the capsule is found.
Small amounts of low mass residual capsule are detected in the
LPS preparation taken from the Triton X114 fraction (Figure 4,
Panel C, lane 3). The anti-LPS MAb FB11 reacts with both the
high molecular weight capsule, and also the O-antigen of the LPS
(Figure 4, Panel D, lanes 2 and 3). The absence of a high
molecular weight band reacting with this MAb in the LPS lane
indicates that there is very little capsule material present in the
LPS sample. The absence of the bands corresponding to the O-
antigen repeating unit of the LPS in the capsule sample indicates
that LPS is essentially absent from the final capsular preparation
(Figure 4, Panel D, lane 2).
Physicochemical analysis of the F. tularensis capsule
Compositional analyses of the capsule by MALDI-MS and
GC-MS. The mass spectrometry (MS) approach we used to
provide critical composition and sequence information on the
capsule was based on methods we employed earlier for LPS and
endotoxin [17,18]. We examined the capsular material both
directly and after limited HF treatment using matrix-assisted laser
desorption ionization mass spectrometry (MALDI-MS) on an
LTQ linear ion trap instrument coupled to an intermediate
vacuum vMALDI ion source. In both cases, initial positive-ion MS
data indicated that there was a 792 Dalton (Da) repeat unit.
Figure 5 shows MALDI-MS analyses of unprocessed capsule in the
positive ion mode. These data show that the predominant
protonated species observed in the MS spectrum is one Da
higher at m/z 793. In addition, monoisotopic masses observed at
m/z 1585, 2377 and 3170, correspond to the addition of one, two
or three of the 792 Da repeating units to the original structure,
respectively. Data observed using MALDI-time of flight (MALDI-
TOF) analyses, which allowed us to observe a larger mass range
than the vMALDI, yielded similar results; a 792 Da repeating unit
was observed, with data obtained for up to six repeating units
(Figure S2, Table S1). Similar to what was observed for the
unprocessed capsule sample, MALDI-MS analyses of the limited
HF-treated capsule also showed the presence of a 792 Da
repeating unit (Figure S3). In limited HF treatment the capsule
underwent chemical hydrolysis to generate oligosaccharide
fragments, so unlike the fragments generated in MALDI-MS in
the unprocessed capsule which were derived from gas-phase
Table 1. Reactivity of F. tularensis strains and mutants with
11B7 and anti-LPS MAb FB11.
Strain
Capsule
1
positive
LPS
2
O-antigen
F. tularensis SHU S4 Yes Yes
F. tularensis LVS-FDA Yes Yes
F. tularensis LVS-VT Yes Yes
F. tularensis 1547 Yes Yes
F. tularensis 1547msbB Yes No
F. tularensis 1547msbB [pmsbB] Yes Yes
F. tularensis 0673-0674 Yes No
F. tularensis 1623 Yes Yes
F. tularensis T1 0902 Yes Yes
F. tularensis WY96-3418 Yes Yes
F. tularensis MA00-2987 Yes Yes
F. tularensis NR-50(NIH B-38) Yes Yes
F. tularensis OSPHL 2001-1011 Yes Yes
F. tularensis OSPHL 2001-1-0513 Yes Yes
F. tularensis OSPHL 2002-1-0990 Yes Yes
F. tularensis OSPHL 2001-1-0074 Yes Yes
F. tularensis OSPHL 2001-1-0143 Yes Yes
F. tularensis LVScapB Yes Yes
F. tularensis LVScapC Yes Yes
F. tularensis LVSwbtC No No
F. tularensis LVSwbtK Yes Modified*
F. tularensis LVS0708 No Yes
F. tularensis LVSwbtM No No
F. tularensis LVSwbtK No No
F. tularensis LVSwbtA1 No No
F. tularensis LVSwbtA2 No No
F. tularensis LVSwbtI No No
F. tularensis LVS FTT0706 Yes No
F. tularensis SCHU S4 0673-0674 Yes No
F. novicida U112 No No
*high mass O-antigens absent compared to parent strain.
1- Reacted with MAb 11B7 to high mass structure on Western blot.
2- Reacted with MAb FB11 demonstrating O-antigen subunits.
doi:10.1371/journal.pone.0011060.t001
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in mass by the addition of water (M=792+18=810).
Multi-stage mass spectrometry (MS
n) of the unprocessed capsule
was utilized to determine the individual components of the
repeating unit (Figure 5). MS/MS analyses of the monoisotopic
mass [M+H]
+ =793 generated two major fragments at m/z 620
and 404 and several minor fragments at m/z 606, 577, 433, 390,
and 361. The mass at m/z 620 corresponds to the loss of 173 Da
from the m/z 793 precursor ion. MS
3 fragmentation of the m/z
620 peak resulted in one major fragment at m/z 404 and two
minor fragments at m/z 433 and 217. The fragment at m/z 404
corresponds to the loss of 216 Da from the m/z 620 precursor ion.
The peak observed at m/z 433 corresponds to the loss of 187 Da
from the m/z 620 precursor ion. MS
4 fragmentation of the
precursor ion at m/z 404 showed fragments that corresponded to
the loss of either 187 or 216 Da. These data demonstrated that
the 792 Da unit is a tetrasaccharide containing two 216 Da
components, one 187 Da component, and one 173 Da compo-
nent. Further analyses using MS
n of the various observed frag-
ment ions originating from the protonated tetrasaccharide,
[M+H]
+=793, gave several disaccharide fragments that defined
various nearest neighbor combinations: 216-216 (m/z 433),
187-216 (m/z 404), 173-216 (m/z 390), and 173-187 (m/z 361)
(Figure 5, Figures S4 and S5, Table 2). These data demonstrated
that the sequence of these constituents was either 187-173-216-216
or 216-216-173-187. This composition and sequence is consistent
with the previously published O-antigen structure for this strain of
F. tularensis [19].
Compositional analyses of the capsule monosaccharides by
high-pH anion exchange chromatography demonstrated that the
capsule sugars were not common monosaccharides, as the major
peaks seen in the capsule sample did not correlate with a standard
mix of twelve standards (Tables S2 and S3). These data also
showed that one of the LPS building blocks, Kdo, was not detected
in the capsule sample. Further compositional analyses using GC-
MS were also performed. GC-MS analyses of alditol acetate (AA)
sugars from the capsule showed the presence of QuiNAc and two
additional peaks which likely correspond to anhydro degradation
products of Qui4NFm or QuiNAc (6, Panel A). Assignments of the
peaks were confirmed by both CI and EI analyses (Figure S6,
Panels B-C). Analyses of AA sugars of the LPS gave the same three
peaks as the capsule sample, and additional LPS sugars, N-
acetylglucosamine (GlcNAc) and N-acetylgalatosamine (GalNAc)
(Figure S7). GC-MS analyses of the capsule as a TMS derivative,
confirmed the presence of QuiNAc and HexNAcAN in the sample
(Figure S8, Table S4). Supplemental Figure S8 shows the GC-MS
analyses of TMS-derived LPS from the same strain of F. tularensis
from which the capsule was extracted. These data demonstrated
Figure 2. Figure 2 shows the results of immunoelectron microscopic studies of surface labeling with MAb 11B7. Figure 2A is a whole
mount immunoelectron microscopy study that demonstrates surface labeling of F. tularensis SCHU S4 with 12 nm colloidal gold particles and
Figure 2B is a secondary only control for the whole mount study. Figure 2C shows a cryo-immunoelectron micrograph of F. tularensis LVS stained with
MAb 11B7 and 12 nm colloidal gold. It shows circumferential staining of capsule material on the surface of the organism. Figure 2D shows the
secondary antibody control section. Magnification is 15, 0006.
doi:10.1371/journal.pone.0011060.g002
Capsule of F. tularensis
PLoS ONE | www.plosone.org 4 July 2010 | Volume 5 | Issue 7 | e11060that the LPS sample contained glucose, mannose, Kdo, GlcNAc,
as well as components of the lipid A (C14:0, C16:0, 3- OH C16:0,
and 3-OH C18:0) (Figure S9, Table S5). When these same
samples were scanned for amino sugars, the presence of QuiNAc,
GalNAc, and GlcNAc was also confirmed. Unlike the LPS sample,
none of the LPS-specific components (Kdo or lipid A) were
detected in the TMS-derived capsule sample. Partial linkage
determination was performed by GC-MS analyses of partially
methylated alditol acetates generated from capsule; these data
demonstrated the presence of a terminal- and a 3-linked-QuiNAc
in this structure (Figure S10).
The present studies strongly suggest that the capsule contains
the same carbohydrate repeating unit as the O-antigen but that it
is a distinct structure from the LPS. Compositional analyses of the
LPS and capsule showed that while both the Kdo and lipid A
components were clearly present in the LPS sample, they were
never detected in the capsule sample. In addition, negative-ion
MALDI-MS data of unprocessed LPS and unprocessed and
HF-treated capsule showed that the monoisotopic mass corre-
sponding to the previously characterized F. tularensis tetraacyl lipid
A, [M-H]
-=1504 [18], was readily detected in the LPS sample,
whereas no masses corresponding to any species of F. tularensis lipid
A were detected in any capsule samples (Figure 6). MS
n analyses of
the LPS sample confirmed that the peak at m/z 1504 was lipid A
(data not shown). These data coupled with our genetic, chemical,
and antibody specificity studies indicate that the capsule is
distinct from the F. tularensis LPS even though both share the same
O-antigen subunit structure.
NMR studies. NMR spectra were analyzed to determine if
assignments of the capsular extract could be made that are con-
sistent with the carbohydrate composition of the polysaccharide as
determined by mass spectrometry. All data are related back to a
13C-HMQC experiment. Spin systems were built up starting from
the anomeric position and extended sequentially using COSY and
short (20 ms) mixing time TOCSY data. A longer (60 ms) mixing
time TOCSY data set was used to both extend and further verify
sequential connectivities. Connections between spin systems were
made using a combination of NOESY data correlating spins near
Figure 3. Figure 3 demonstrates chromatographic separation
using Sephacryl SH500 that shows the separation of Francisella
capsule from the LPS. Panel A is a ProQ Emerald green stained SDS-
PAGE showing the results of column separation. The capsule can be
seen in lanes 13 and 14 and the LPS in lanes 21 and 23. Lane S is an
aliquot of the sample after proteinase K and phenol extraction and prior
to Triton X-114 extraction. Panel B is an immunodot assay of each
fraction using MAb 11B7. The numbers in the panels correspond to
aliquots from each one ml fraction from the column.
doi:10.1371/journal.pone.0011060.g003
Figure 4. Figure 4 shows a silver stained gel (panel A), ProQ Emerald Green glycostained gel (panel B), a Western blot with the anti-
capsule MAb 11B7 (panel C) and a Western blot with MAb anti-LPS MAb FB11 (panel D), Lane S is the molecular weight standard,
lane 1 contains the crude capsule prep before Triton X114 treatment, lane 2 contains the capsule preparation after Triton X-114
treatment and lane 3 contains LPS separated into the Triton X114 fraction. This contains minimal amounts of residual capsule.
doi:10.1371/journal.pone.0011060.g004
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connections to spins across the glycosidic linkage.
Analysis of mass spectrometric data indicated a 4 subunit repeat
with masses arranged either 216-216-173-187 or 187-173-216-216,
as the MS analysis data did not differentiate the reducing and non-
reducing ends. There is little data consistent with the first model:
no inter-ring HMBC crosspeaks, a single cross-glycosidic NOE of
dubious merit, and only three other weak NOEs. However, there is
Figure 5. Figure 5 shows positive ion vMALDI-LIT mass spectra of unprocessed capsule. Gas-phase fragmentation of the intact capsule
allowed fragments of the capsule to be observed by MS analyses. The MS
n spectrum (A) of the capsule demonstrated that the predominant mass
observed in the spectrum was at m/z 793. The presence of structures consisting of a 792 Da saccharide repeating unit with one (m/z 793), two (m/z
1585), three (m/z 2377), or four (m/z 3170) saccharide repeats were detected. MS
n analyses, using collisionally induced dissociation, of a single unit
tetrasaccharide at 793 m/z (B) yielded a number of fragment ions. The predominant fragment ions were sequentially fragmented to yield MS
3 data of
m/z 620 (C) and MS
4 data of m/z 404 (D). The MS
4 data of m/z 404 demonstrated that it is composed of two carbohydrate monomers with nominal
masses of 187 and 216 Da, and that these sugars are located adjacent to one another. Masses labeled with an * designate major masses +/2 water.
doi:10.1371/journal.pone.0011060.g005
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has a proposed composition 4)-a-D-GalNAcAN-(1-.4)-a-D-GalNA-
cAN-(1-.3)-b-D-QuiNAc-(1-.2)-b-D-Qui4NFm-(1-..T h i si st h e
same structure determined by Vinogradov et al. for the F. tularensis O-
antigen [20]. Assignments for the individual spin systems are shown
in Table 3 and Figure 7 with the GalNAcAN subunits labeled A and
B from the non-reducing to the reducing end of the molecule. Cross-
glycosidic HMBC crosspeaks were observed between GalNAcAN(A)
C1 and GalNAcAN(B) H4 as well as between GalNAcAN(B) C1 and
QuiNAc H3, although no inter-ring HMBC crosspeaks were
observed involving Qui4NFm. A number of NOEs that were also
observed between subunits are summarized in Table 4.
One result from the NMR data that was unexpected is the
presence of a number of stronger resonances in the HMQC
spectrum. The total number of these stronger signals, as well as
just those in the anomeric region of the spectrum, would seem to
indicate the presence 2 or 3 additional sugars or breakdown
products of the identified sugars. The MS data previously
described, however, is clean and only indicates the presence of a
single tetrasaccharide repeat. A more intense resonance in an
NMR spectrum can arise in one of two circumstances. The first is
that there is a greater concentration of that spin relative to the rest
of the spins in the spectrum. This possible explanation could point
Table 2. Proposed compositions of masses observed by
MALDI-MS
n analyses.
[M+H]
+
observed [M+H]
+
calculated GalNAcAN
1 QuiNAc
1 Qui4NFm
1
793.17 793.32 2 1 1
620.17 620.17 2 1 0
606.17 606.23 2 0 1
577.17 577.24 1 1 1
433.17 433.16 2 0 0
404.25 404.17 1 1 0
390.25 390.15 1 0 1
361.17 361.16 0 1 1
1GalNAcAN: 2-acetamido-2-deoxy-D-galacturonamide (M=216.08 Da), QuiNAc:
2-acetamido-2,6-dideoxy-D-glucose (M=187.09 Da), and Qui4NFm: 4,6-
dideoxy-4-formamido-D-glucose (M=173.07 Da). Masses listed are dehydro
forms of each constituent.
doi:10.1371/journal.pone.0011060.t002
Figure 6. Figure 6 shows a negative-ion vMALDI-MS analyses of LPS (A) and capsule without (B) and with (C) HF treatment. The F.
tularensis tetraacyl lipid A is readily detected in the LPS sample, but is not seen in either of the capsule samples.
doi:10.1371/journal.pone.0011060.g006
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that co-purified with the capsular polysaccharide. The second way
more apparently intense peaks can arise in a spectrum is if the
spins giving rise to those resonances are more mobile (i.e. faster
relaxing) than the rest. This explanation could point to a more
flexible substituent branched off the main polysaccharide. Which
possible explanation, if either, is correct remains unclear.
Studies of capsule expression in F. tularensis biosynthesis
pathway mutants. Using mutants in F. tularensis LVS of
glycosyltransferases and putative capsule biosynthesis genes (cap)
obtained from Dr. Dara Frank of the Medical College of Wisconsin,
we were able to confirm that the LPS O-antigen biosynthesis
pathway plays a role in the biosynthesis of the F. tularensis capsule
[21]. These studies have demonstrated that mutations that disrupt
glycosyltransferase genes involved in O-antigen biosynthesis (wbtI,
wbtA1, wbtA2, wbtM, wbtI and wbtC) resulted in the loss of capsule
expression (Figure 8). Mutations in F. tularensis LVS capB and capC
had no effect on capsule expression. However, a mutation in wbtK
resulted in loss of high mass O-antigen expression but did not affect
capsule expression (data not shown). The Kdo-dependent
acyltransferase mutant, F. tularensis lpxL, which expresses a portion
of the LPS core region but no O-antigen, still produces capsule
(Figure 9).F. tularensis LVSFTL0706,which has complete homology
to the O-antigen polymerase of F. novicida, does not express O-
antigens yet still expresses the capsule (Table 1). In addition, a Tn5
mutation in the promoter region of F. tularensis SCHU S4 between
open reading frames FTT0673-0674 resulted in a mutant that
produced a capsule but the mutant does not express a full length
O-antigen. FTT0673c has been annotated as a gene of unknown
function and FTT0674 is annotated as a ribose-phosphate
pyrophosphokinase. These studies demonstrate that O-antigen
and capsule are linked at a number of points in the biosynthetic and
assembly pathway but there appear to be several points in transport
and assembly that are different.
Passive immunization of BALB/c mice with 11B7 MAb
against challenge with F. tularensis LVS. We performed an
experiment to determine whether mice would be protected from
lethal Francisella infection by administration of purified monoclonal
antibody 11B7. Two groups of five mice received 75 mg of purified
MAb 11B7 and 24 hours later were challenged intraperitoneally
with either 5610
4 or 5610
5 colony forming units (cfu) of F.
tularensis LVS. A third group of mice received 75 mg of a control
isotype matched MAb 2C3 that binds to a Neisseria gonorrhoeae
membrane protein. All animals were followed for two weeks after
challenge. As shown in Figure 10, administration of MAb 11B7
provided complete protection to BALB/c mice against .100 LD50
doses of F. tularensis LVS for more than 14 days, while all of the
mice receiving the control MAb 2C3 succumbed to the infection
by day 6. In Figure 10, survival of all mice given MAb 11B7 was
significantly different from the MAb 2C3 control mice (log-rank
p=5.1610
25), and survival of immunized mice at any one of the
two doses of MAb 11B7 was also significantly different from the
MAb 2C3 control group (p=1.6610
-4). The passively immunized
mice remained active, did not develop ruffled fur or stop eating or
drinking.
Active immunization of BALB/c mice with capsule and
challenge with F. tularensis. To determine if the F. tularensis
capsule could protect mice against a lethal challenge, BALB/c
mice were immunized intraperitoneally twice 30 days apart with
50 ml containing 10 mg of capsule in PBS mixed with an equal
amount of TiterMax Gold adjuvant. Control mice received 50 ml
of PBS mixed with the same adjuvant on the same schedule. Eight
days after the second injection, a group of five of the control mice
was challenged with 250 cfu of F. tularensis LVS. A second group of
four control mice received 750 cfu of F. tularensis LVS. One group
of five mice immunized with capsule was challenged with
5610
4 cfu and a second group of five immunized mice also
immunized with capsule received 5610
5 cfu of F. tularensis LVS.
Figure 11 shows the results of these studies. These data
demonstrated that in the PBS controls samples, 50% of the
control mice receiving 250 cfu and 60% of the control mice
receiving 750 cfu, died by day 5. All of the mice immunized with
capsule survived a challenge of up to 5610
5 F. tularensis LVS with
no evidence of infection and were euthanized at day 14. In
Figure 11, in spite of the fact that the capsule immunized group of
mice received a dose of LVS up to 666 times greater than the PBS
control animals, survival of all mice immunized with capsule was
significantly different from all the control mice (p=6.9610
-3). The
actively immunized mice remained active, did not develop ruffled
fur or stop eating or drinking.
Western blot analyses (Figure 12) and ELISA performed on sera
from the immunized mice demonstrated that all had IgG and IgM
reactivity to the capsule and no detectable reactivity to F. tularensis
LPS. Simultaneous ELISA studies showed that antibody persisted
after vaccination for at least 14 days.
Discussion
Capsular polysaccharides have been shown to be important
virulence factors in a wide range of bacterial species. F. tularensis
has been considered to be encapsulated but the precise nature of
the capsular antigen has never been elucidated. Unreferenced
comments in Zinsser Microbiology [22], state that there is a single
immunotype of F. tularensis. Carlisle in 1962 used Ouchterlony
plates to compare the immunogenicity of crude extracts from four
strains of F. tularensis and a ‘‘polysaccharide’’ isolated from a fifth
strain [13]. These studies showed immunological identity between
the polysaccharide fraction and the four bacterial extracts, leading
to the conclusion that there was a common carbohydrate structure
in the five F. tularensis strains. Hood studied a relatively unrefined
extract of F. tularensis and did preliminary investigation of sugars
Table 3. NMR Chemical Shift Assignments.
Sugar
H1 H2 H3 H4 H5
a-D-GalNAcAN 5.09 4.07 4.26 4.51 4.86
A (non-reducing) C1 C2 C3 C4 C5
100.1 53.7 73.1 82.2 72.8
a-D-GalNAcAN H1 H2 H3 H4 H5
5.4 4.24 4.02 4.44 4.04
C1 C2 C3 C4 C5
100.9 51.8 70 78 70.1
b-D-QuiNAc H1 H2 H3 H4 H5 H6
4.75 3.72 3.66 3.34 3.44 1.2
C1 C2 C3 C4 C5 C6
104.4 57.5 82.4 78.9 74.4 18.9
b-D-Qui4NFm H1 H2 H3 H4 H5 H6
4.41 3.53 3.52 3.62 3.43 1.19
C1 C2 C3 C4 C5 C6
105.3 83 76.8 58.5 73.3 19.5
doi:10.1371/journal.pone.0011060.t003
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His studies found heptose, glucose, galactose, mannose, rhamnose
and possibly dideoxy sugars in the cell wall and mannose, rhamnose
and possibly dideoxy sugars in the ‘‘capsular’’ preparation. No
further characterization was performed. Studies by Sorokin and
Sandstromhaveshownthatacapsular(basedoncolonymorphology
andelectronmicroscopy)F.tularensisstrains aresensitivetokillingby
bactericidal antibody [14,15]. Sorokin did not describe how the
acapsular status of the strain was produced or verified. Sandstrom
used acridine orange mutagenesis to create a mutant library which
was screened for "rough" colonies on solid media; the ‘‘rough’’
colonies were designated as lacking capsule. Electron micrographs
showed changes consistent with loss of a capsular structure [15] in
the mutants that were selected. However, no studies of the
compositionor the nature of the mutationsleadingto the phenotype
were described. Using tagged mutagenesis, Su and colleagues
recently showed that mutations in an operon, they designated
capBCA, led to an avirulent phenoype in mice [23]. They considered
these to be putative capsule genes because of their partial homology
to the poly-c-glutamate capsule biosynthesis locus of Bacillus
anthracis. Our studies would suggest that this locus plays no role in
the synthesis of the F. tularensis O-antigen capsular polysaccharide
(Figure 8). Whether it encodes for a second capsule-like antigen or
another virulence factor is unclear.
We have demonstrated a method for the purification of the F.
tularensis capsular polysaccharide and have demonstrated that F.
tularensis type A and type B strains produce an O-antigen capsule
composed of repeating O-antigen subunits, 4)-a-D-GalNAcAN-(1-
.4)-a-D-GalNAcAN-(1-.3)-b-D-QuiNAc-(1-.2)-b-D-Qui4NFm-
(1-. Monoclonal antibody FB11, which reacts with the O-antigen,
also binds to the capsule. We believe our success in identifying the
capsule was due to developingthe MAb 11B7 which permittedus to
use it as a means of tracking the polysaccharide during isolation
since in addition to the O-antigen epitopic structure, this capsule
also has an epitopic structure distinct from the LPS as defined by
monoclonal antibody 11B7. This antibody was generated by
immunizing mice with the capsule preparation which subsequently
resulted inthe evolutionofantibody 11B7.Thisantibody appearsto
react only with the capsule suggesting that this is the immunodo-
minant epitope on that structure. It should be noted that in our
monoclonal antibody development, using material obtained from
saline washed cells as the immunogen, we did not raise an antibody
Figure 7. Figure 7 demonstrates
1H-
13C HMQC spectrum of F. tularensis capsule polysaccharide collected at 600 MHz and plotted
near the noise floor. Methyl and formyl resonances were aliased in the
13C dimension to optimize the spectral window. Assignments for each sugar
in the core tetrasaccharide are indicated in a different color, and the dashed lines connect the resonances within each spin system. The indicated
assignments are highly consistent with those for the O-antigen tetrasaccharide [45,46].
doi:10.1371/journal.pone.0011060.g007
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amounts or absent from the preparation.
Our studies have shown that the F. tularensis capsule is a
repeating polymer of the O-antigen of the LPS. Goldman and co-
workers first showed that Escherichia coli 0111 expressed a non-LPS
surface polysaccharide composed of O-antigens [24,25]. Subse-
quently, a number of Gram-negative bacteria have been shown to
express similar structures which consist of large repeating subunits
not linked to the LPS core region or lipid A [26,27,28,29]. A
review by Whitfield expands the description of the different
capsule types and segregates them into specific Groups based on
their characteristic structures [30]. Group 1 and 4 capsules of
Enterobacteriaceae are composed of LPS O-antigens [30]. In strains
in which the capsule structure is linked to a lipid A core, it is
termed a KLPS to distinguish it from the LPS molecules on the
same organism. Other strains may have O-antigen capsules that
lack the lipid A core but have another yet unidentified structure
which anchors them to the cell wall. These are known as K
Figure 9. Figure 9 is a Western blot which demonstrates loss of
O-antigens but persistence of capsule in F. tularensis lpxL. Panels
A and B show F. tularensis LVS (lane 1), F. tularensis 1547lpxL (lane 2) and
F. tularensis 1547lpxL complemented with lpxL (lane 3). Panel A was
reacted with the F. tularensis anti-LPS MAb FB11 and panel B was
reacted with the F. tularensis anti-capsule MAb 11B7.
doi:10.1371/journal.pone.0011060.g009
Figure 10. Figure 10 shows the results of protection of BALB/c
mice passively immunized with MAb 11B7 from lethal infection
due to F. tularensis LVS. Five mice received 75 mg of MAb 11B7 and
were challenged with 1610
4 cfu (&), five mice received 75 mg of MAb
11B7 and were challenged with 1610
5 cfu (n) and five mice received
75 mg of MAb 2C3 a Neisseria H.8 MAb as a negative control (X) and
were challenged with 10
4 cfu. As can be seen, MAb 11B7 was protective
while all of the mice receiving the control antibody died by day 6 after
challenge.
doi:10.1371/journal.pone.0011060.g010
Table 4. NOEs Observed Between Sugar Moieties.
Inter-ring NOEs observed (grouped by linkage)
GalNAcAN(A) H1 GalNAcAN(B) H4 glycosidic
GalNAcAN(B) H1 QuiNAc H3 glycosidic
QuiNAc H4
QuiNAc H6
GalNAcAN(B) H2 QuiNAc H3
QuiNAc H1 Qui4NFm H2 glycosidic
Qui4NFm H1 GalNAcAN(A) H4 glycosidic
GalNAcAN(A) H5
Qui4NFm H2 GalNAcAN(A) H4
GalNAcAN(A) H1* GalNAcAN(B) H3, H5*
GalNAcAN(A) H2* GalNAcAN(B) H4*
QuiNAc H1* Qui4NFm H1, H3*
QuiNAcH6* Qui4NFm H3, H4, and formyl*
Qui4NFm H1* GalNAcAN(A) H3*
Additional possible NOEs*
*the NOEs listed in this section have characteristics that make them less than
ideal, i.e. they fall as a shoulder of another peak, under an intra-ring NOE, are
very weak, or lie near the residual water signal.
doi:10.1371/journal.pone.0011060.t004
Figure 8. Figure 8 is a Western blot developed with MAb 11B7
showing whole organism lysates from F. tularensis 1547 (lane
1), F. tularensis LVS wbtI, wbtA2, wbtA1, capB, capC, and wbtC in
lanes 2–7 respectively. F. tularensis LVS is in lane 8.
doi:10.1371/journal.pone.0011060.g008
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sugars as a component of the capsule indicating that the Francisella
capsule is probably a K antigen. E. coli group 1 capsules are acidic
and typically contain uronic acid structures while group 4 capsules
tend to be more diverse and can be distinguished from group 1
capsules by the presence of acetamido sugars in their repeat
subunits [30]. The F. tularensis capsule fits this characteristic by
having two 2-acetamido-2,6-dideoxy-O-D-glucose (O-QuiNAc),
4,6-dideoxy-4-formamido-D-glucose (O-Qui4NFm), and 2-aceta-
mido-2-deoxy-O-D-galacturonamide (O-GalNAcAN) in each O-
antigen tetrasaccharide subunit. The genetic organization of
capsular genes from a number of bacterial species have been
described [31]. The assembly and transport systems involved in
production of these capsules are complex and include activators of
sugar precursors, glycosyltransferases and then a complex of
transport and assembly proteins to move these large macromol-
ecules from the periplasm to the cell surface. Group 4 capsule
initiation involves transfer of N-acetylglucosamine-1-phosphate to
undecaprenol phosphate by WecA followed by the addition of the
individual components of the capsular O-antigen subunit to this
lipid carrier. The polymerization systems, periplasmic ligase and
transport proteins appear to be similar for the group 1 and 4
systems. However, the lengths of the O-antigen repeats in the
respective capsules are different. In group 1 the capsule repeats
tend to be limited to one or a few O-antigen subunits while the
group 4 capsules tend to form long chain O-antigen repeats. The
difference in KLPS chain lengths in group 1 and 4 is considered to
be due to the absence of wzz (the O-antigen chain length
determinant) in isolates with group 1 capsules [32]. In an analysis
of the F. tularensis SCHU S4 genome using the hidden Markov
model, we have homologs of proteins involved in assembly of the
capsule, WbtB, Wzx, Wzb and WecA, but no proteins in F.
tularensis with homologies to capsular transport proteins in the
enteric family, gammaproteobacteria.
Our observation that the F. tularensis lipid A acyltransferase
mutant, lpxL and F. tularensis LVS O-antigen polymerase mutant,
FTL_0706, did not express repeating O-antigens is not surprising.
Analysis of the Western blot using the O-antigen monoclonal
antibodies indicated that the polymerase mutant produced an LPS
consisting of a core region plus one O-antigen subunit. The fact
that the capsule was still expressed in the O-antigen polymerase
mutant indicates that the pathways for the polymerization
processes are different and suggests that the O-antigen ligase
and polymerase are distinct genes in Francisella. The lpxL mutant
expresses only a portion of the LPS core region, but still produces
a capsule. The reason for the loss of O-antigen expression in the
lpxL mutant is less obvious than with the polymerase mutant.
Studies in a similar acyltransferase mutant in Neisseria meningitidis
serogroup B resulted in an organism which failed to transport LPS
to the bacterial surface [33]. It is known that encapsulated Gram-
negative bacteria can survive without LPS in the outer membrane
[34]. In the N. meningitidis lpxL mutant, evidence of the LPS
terminal structures could be identified accumulating in the
cytoplasm of the bacterium while no LPS could be identified on
the cell surface. This would suggest that in F. tularensis lpxL the O-
antigen defect may be related either to inability of the LPS to be
transported out of the cell interior or to a failure of the polymerase
to add additional O-antigen subunits to the nascent core-O-
antigen structure. These results would indicate that the transport
pathway and/or assembly pathways for the LPS and capsule are
distinct.
Finally, the active and passive immunization studies indicate
that the epitope defined by 11B7 is protective against a lethal
challenge of F. tularensis LVS in mice. The post-immunization sera
indicated that the only epitopic structure detectable was to the
capsule in spite of the fact that it is composed of O-antigen
subunits. Our IgG and IgM studies in the immunized mice
suggested that there was evidence of both isotypes of antibody
being generated. At this time, it is premature to determine if both
or one of the two isotypes provided the protection that was
demonstrated.
These studies provide evidence for a capsular polysaccharide of
F. tularensis. This polysaccharide is a polymer composed of the LPS
O-antigen subunit, 2-acetamido-2,6-dideoxy-o-glucose (o-Qui-
NAc), 4,6-dideoxy-4-formamido-D-glucose (o-Qui4NFm), and 2-
acetamido-2-deoxy-o-galacturonamide (o-GalNAcAN). It appears
to be conserved across F. tularensis type A and B strains. Passive
and active protection assays suggest that this may be a useful
immunogen to protect against lethal infection. Future studies will
include immunization of BALB/c mice with these capsular
preparations by the intraperitoneal and intranasal route followed
by intranasal challenge with F. tularensis SCHU S4 and other more
virulent strains to more fully determine the usefulness of these
immunogens as a vaccine.
Materials and Methods
Strains and culture conditions
Bacterial strains used in this study are listed in Table 5. All F.
tularensis strains were grown at 37uC on chocolate agar medium
supplemented with IsoVitaleX for a final cysteine concentration of
0.1%.
Transposon selection protocol
A Francisella-specific Tn5 transposon system has been developed
by our group that is delivered by a temperature sensitive plasmid
Figure 11. Figure 11 shows the results of immunization of
BALB/c mice with 2 doses of 10 mg F. tularensis capsular antigen
at a four week interval. Capsule immunized mice were challenged a
week after the second dose with either 1610
4 (6 )o r5 610
5 (N) F.
tularensis LVS. Control mice received PBS and were challenged with
either 250 cfu (m) or 750 cfu (&)o fF. tularensis LVS. As can be seen,
these results indicate that the capsular antigen is protective against a
challenge 666-fold higher than the LD50 for F. tularensis in mice. Each
group contains 5 mice.
doi:10.1371/journal.pone.0011060.g011
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introduced into F. tularensis SCHU S4 by cryotransformation [36].
Colonies obtained after ,3 days growth at 30uC on MMH agar
containing 25 mg/ml spectinomycin were inoculated into 5 ml
MMH broth with 25 mg/ml spectinomycin and were grown at
30uC with agitation to an OD600 of ,0.2. Selection of F. tularensis
SCHU S4 transposition events was performed at 40uC with ,10
8
organisms plated. Since transposition frequency has previously
been shown to be ,10
23, approximately 10
5 random chromo-
somal transposon mutants were created by this procedure.
Individual F. tularensis Tn5 mutant colonies (,7,500 mutants)
were picked and arrayed into 96-well cell culture plates in 100 ml
MMH broth and were incubated at 37uC until turbid. Freezer
stocks were made by adding 100 ml of 2X freezing medium (1.0 M
sucrose, 20% glycerol).
Development of hybridomas producing antibodies to
the capsule of F. tularensis
BALB/c mice were immunized intraperitoneally with 25 mlo f
a 1 mg/ml solution of a high salt extract of F. tularensis subsp.
tularensis SCHU S4 prepared according to the method of Hood
[16]. Animals were reimmunized at day 21 and day 28. Sera
from the immunized mice was tested for antibodies to the
immuning extract in ELISA. After confirmation of high antibody
titers (.1:10,000), animals were sacrificed 4 days later and their
spleens removed. The splenocytes were recovered and fused to
SP2/0 murine myeloma cells using 40% polyethylene glycol
(1540 MW). Selection was accomplished by plating the fused
cells in the presence of hypoxanthine-aminopterin-thymidine
DMEM and plated in limiting dilutions to achieve approximately
1 - 5 cells per well. When colonies appeared, supernatants were
tested for presence of antibodies against the saline extract in
ELISA. Supernates which proved to be positive in ELISA were
tested in Western blot. After this testing, MAb 11B7 fit our
criteria as a possible anti-capsular antibody. MAb 11B7 was
determined to be an IgG1k using Isostrips (Santa Cruz
Biotechology, Inc, Santa Cruz, CA). MAb 11B7 was recloned
to assure purity and antibodies produced from these lines for use
in this study.
Screening mutants for reduced capsule and identification
of the transposon insertion site
In the BSL-3 facility, F. tularensis SCHU S4 Tn5 mutants were
inoculated into duplicate 96 well dishes containing MMH broth
and were grown until turbid. Cultures were killed by adding
100 ml of 4% paraformaldehyde to each well and incubating
overnight. After ensuring sterility, the plates were removed from
the BSL-3 facility and the liquid was removed by evaporation. The
capsule produced by each organism was then quantitatively
determined by ELISA using capsule-specific antibody.
Figure 12. Figure 12 is a composite Western blot using sera from capsule immunized mice. A goat anti-mouse IgG peroxidase conjugate
was used to develop panel A and a goat anti-mouse IgM peroxidase conjugate was used in panel B. All sera were tested at a 1:1000 dilution. C1 and
C2 represent sera from animals given PBS only. One strip has been reacted with MAb 11B7 as a control for capsule using the goat anti-mouse IgG
peroxidase conjugate.
doi:10.1371/journal.pone.0011060.g012
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production, chromosomal DNA was isolated from individual
mutants and digested with EcoRI to create a DNA fragment with
the oriR6K origin, the aphA3 gene and flanking chromosomal
sequence. The digested DNA was ligated, transformed into a pir
+
E. coli strain and plated onto agar plates with kanamycin to select
for transformants that carried the plasmid of interest. Plasmid
DNA was isolated and sequenced using a primer with the
sequence 59CATGCAAGCTTCAGGGTTGAG 39 that anneals
to the 39 end of the aphA3 gene and produced sequence of the
flanking chromosomal DNA. Sequence data was used to search
the sequenced bacterial chromosomal database using NCBI
BLAST to identify Tn5 insertion sites within the F. tularensis
chromosome.
Isolation of the Francisella capsule
Bacteria were grown as a lawn for approximately 48 h on
chocolate agar medium plates at 37uC and were collected by
scraping colonies from the surface and suspending these in a
solution of 6 mM Trizma base (Research Products International
Corporation, Mt. Prospect, IL), 10 mM EDTA (Fisher Scientific,
Fair Lawn, NJ) and 2.0% SDS (w/v) (Research Products
International), pH 6.8 containing 50 mg/ml proteinase K and
incubated at 65uC for 1 h and then overnight at 37uC. Additional
Tris-SDS solution was added to completely solubilize the bacterial
pellet after the 65uC incubation. The sample was placed at 37uC
in a dry incubator overnight to complete the digestion. To remove
the SDS, one tenth the volume of 0.3 M sodium acetate (0.1 ml
per 1 ml sample) was added to the samples which were then
precipitated with 3 volumes cold 100% ethanol, flash cooled in a
dry ice-ethanol bath and incubated overnight at 220uC. Samples
were centrifuged for 10 min at 12,0006g at 4uC and pellets were
suspended in deionized water and precipitated a total of three
times. Samples were suspended in 15 ml of 10 mM Tris pH 7.4
containing 10 mM CaCl2 and treated with 80 U micrococcal
nuclease (Sigma, St. Louis, MO) overnight at 37uC. After
incubation, an equal volume of 95% phenol was added to this
mixture. Capsule samples and phenol were incubated at 65uC for
30 min, cooled on ice, and centrifuged at 2,0006g for 10 min at
4uC. The aqueous layer was collected and the phenol layer was
back extracted with an equal volume of deionized water pre-
warmed to 65uC. The aqueous layers were combined. To remove
Table 5. Strains used in this study.
Strain Subspecies source ref
F. tularensis SCHU S4 tularensis BEI
F. tularensis LVS-FDA holarctica FDA [47]
F. tularensis LVS-VT holarctica Virginia Tech [48]
F. tularensis 1547 holarctica University of Iowa [49]
F. tularensis 1547lpxL holarctica University of Iowa [49]
F. tularensis 1547lpxL [plpxL] holarctica University of Iowa [49]
F. tularensis 0673-0674 tularensis University of Iowa Apicella
F. tularensis 1623 holarctica University of Iowa
F. tularensis T1 0902 tularensis Virginia Tech
F. tularensis WY96-3418 tularensis BEI
F. tularensis MA00-2987 tularensis BEI
F. tularensis NR-50(NIH B-38) tularensis BEI
F. tularensis OSPHL 2001-1011 tularensis Oregon State Health Lab
F. tularensis OSPHL 2001-1-0513 tularensis Oregon State Health Lab
F. tularensis OSPHL 2002-1-0990 not typed Oregon State Health Lab
F. tularensis OSPHL 2001-1-0074 not typed Oregon State Health Lab
F. tularensis OSPHL 2001-1-0143 not typed Oregon State Health Lab
F. tularensis LVScapB holarctica Medical College of Wisconsin [50]
F. tularensis LVScapC holarctica Medical College of Wisconsin [50]
F. tularensis LVSwbtC holarctica Medical College of Wisconsin [50]
F. tularensis LVSwbtK holarctica Medical College of Wisconsin [50]
F. tularensis LVS0708 holarctica Medical College of Wisconsin [50]
F. tularensis LVSwbtM holarctica Medical College of Wisconsin [50,51]
F. tularensis LVSwbtK holarctica Medical College of Wisconsin [50]
F. tularensis LVSwbtA1 holarctica Medical College of Wisconsin [50]
F. tularensis LVSwbtA2 holarctica Medical College of Wisconsin [50]
F. tularensis LVS FTT0706 holarctica Medical college of Wisconsin [39]
F. tularensis LVSwbtI holarctica Virginia Tech
F. tularensis SCHU S4 0673-0674 tularensis University of Iowa
F. novicida U112 tularensis ATCC
doi:10.1371/journal.pone.0011060.t005
Capsule of F. tularensis
PLoS ONE | www.plosone.org 13 July 2010 | Volume 5 | Issue 7 | e11060residual phenol, one-tenth volume of 0.3 M sodium acetate was
added to the aqueous layers which were then precipitated three
times with 3 volumes of absolute ethanol. The pellet was raised in
distilled water and Triton X-114 (Sigma) was added to a final
concentration of 5% (v/v). The sample was vortexed for 30
seconds and placed at 4uC. Sixteen hours later, the sample was
placed at 37uC for two hours. The resulting detergent aqueous
suspension was centrifuged at 20006g at 37uC for ten minutes and
the upper aqueous phase removed. The aqueous phase was
dialyzed at room temperature against multiple changes of distilled
water over 48 h and lyophilized. For some experiments, the
lyophilized capsule was reconstituted in 6 mM Tris base, 10 mM
EDTA and 2.0% SDS (w/v), pH 6.8 and placed over a 1620 cm
Sephacryl SH500 column equilibrated with the same buffer to
remove residual LPS. The void volume of the column was 11 ml
and the bed volume was 25 ml. The column was run at 37uC.
Immunological assays
Western blots were performed as previously described using 4–
12% gradient gels (Invitrogen, Carlsbad, CA) with samples
transferred to PVDF (Millipore) [37]. ELISA assays were
performed using CoStar 3590 plates (Corning Inc., Corning,
NY) coated with 10 mg/ml of capsule as previously described [37].
Cryoultramicrotomy for Immuno-TEM
F. tularensis colonies were removed intact using a punch and
fixed in 4% paraformaldehyde with 0.2% glutaraldehyde in PBS
overnight at 4uC. The plug was carefully trimmed into 1 mm
square sections, treated with 2.3 M sucrose at 4uC overnight and
then frozen by direct immersion in liquid nitrogen. Ultrathin
frozen sections (70–95 nm) were cut on Leica EM UC6
Ultramicrotome and transferred onto a carbon-coated formvar
covered nickel grid. These samples were then used for immunoe-
lectron microscopy.
Immunogold labeling for electron microscopy
The sections on the nickel grids were washed with PBS and then
distilled water. They were blocked with 5% normal goat serum for
15 min. This was followed by incubation with the primary
antibody, MAb 11B7 at a 1:100 dilution in PBS for 30 min. The
sample was washed with PBS thrice for 2 minutes each time. The
secondary antibody was a goat anti-mouse 12 nm gold conjugate
diluted 1:40 in PBS and incubated on the sample at room
temperature for 30 min. The grid was washed with PBS six times
for 2 min each. As a final step, the grids were stained with 0.3%
uranyl acetate in 2% methylcellulose for 8 min on ice. The excess
solution was removed, the grid dried and the sample viewed with a
JEOL 1230 TEM at an accelerating voltage of 120 kv.
Immunogold studies were also preformed on ‘‘whole mounted’’
bacteria with MAb 11B7 to evaluate surface labeling by the
antibody directly. To accomplish this, bacteria were suspended in
PBS and 5 ml were placed on a formvar coated nickel grid, the
bacteria were allowed to settle for 10 minutes and excess fluid
blotted off carefully with a Kimwipe. The sample was fixed by
flooding the grid with a solution of 4% paraformaldehyde
containing 0.05% ruthenium red. Excess fluid was removed with
a Kimwipe. Five ml of MAb 11B7 at a dilution of 1:500 was placed
on the grid which was incubated at room temperature for 3 hours
in a moist chamber. The grid was washed three times in PBS and a
goat anti-mouse IgG 12 nm immunogold conjugate was placed on
the grid for one hour. The grid was washed three times with PBS
followed by distilled water. The grid was dried and viewed with a
JEOL 1230 TEM at an accelerating voltage of 120 kv.
Compositional analysis
For composition analyses capsule and LPS samples were run as
alditol acetate (AA) and trimethylsilyl (TMS) derivatives. For AA
derivatives, approximately 100 mg of sample was hydrolyzed to
constituent monosaccharides with 4 N HCl at 100uC for 6 h. The
acid was removed by flushing with dry nitrogen and re-evaporated
using a 50% aqueous isopropanol solution. The monosaccharides
were re-suspended in water and analyzed on a Dionex ICS-3000
equipped with a CarboPac PA-1 column, using a Pulsed
Amperometric Detector (PAD). Samples were eluted using a
sodium hydroxide and sodium acetate gradient. A standard set of
monosaccharides were analyzed for comparison purposes. Alter-
natively, the monosaccharides were reduced to the corresponding
alditols with either sodium borodeuteride or sodium borohydride
overnight at room temperature. Reduced samples were neutral-
ized with a 30% acetic acid solution and excess borates were
removed by repeated co-evaporation with acidified methanol and
anhydrous methanol several times. Finally, alditols were acetylated
using a 1:1 mixture of pyridine:acetic anhydride at 100uC for 1 h.
Reagents were removed using a dry nitrogen flush. Samples were
then extracted in dichloromethane and analyzed by GC-MS. For
TMS derivatives, either 100 mg (capsule) or 300 mg (LPS) was
methanolyzed using 1 M methanolic-HCl at 80uC for 16 h
followed by removal of acidified methanol and re-N-acetylation
using CH3OH:pyridine:acetic anhydride (5:1:1, by vol) at 100uC
for 1 h. Reagents were removed by dry nitrogen flush, and the
samples were silylated using Tri-Sil reagent at 80uC for 30 min.
After removal of Tri-Sil by dry nitrogen flush, samples were
extracted in hexane and analyzed by GC-MS. Composition
analyses of capsule and LPS samples were performed on a Trace-
MS Plus GC-MS (Thermo Fisher, Waltham, MA) equipped with
an AS-2000 autosampler and a Rtx-5ms column (15 m60.25 mm,
df=0.25 mm) operating in the electron impact (EI) mode. Two ml
of sample was injected into the GC-MS operating in the split mode
at 220uC, and the sample was split 1:50. The initial oven
temperature was set to 100uC, with a 5 min hold, followed by a
ramping of the temperature at 4uC/min, with a final temperature
of 270uC. Samples run in the chemical ionization mode (CI) were
dissolved in dichloromethane and subsequently analyzed on a
Varian GC-MS equipped with a DB-5 column (15 m60.25 mm,
df=0.25 mm [Varian Inc., Palo Alto, CA]). One ml of sample was
injected into the GC-MS, operating with a split ratio of 1:25. The
initial oven temperature was set to 120uC, with a 2 min hold,
followed by a ramping of the temperature of 5uC/min, with a final
temperature of 240uC, with a 5 min hold. Acetonitrile was used as
the ionizing gas in CI mode.
Linkage analysis
Linkage analysis of the capsule was done following a modified
method of Ciucannu [38]. First, 0.4 mg of the sample was
dissolved in 0.4 mL anhydrous dimethyl sulfoxide (DMSO)
overnight, and then a slurry of sodium hydroxide in DMSO was
added to the sample and incubated at room temperature for 1.5 h
with constant stirring. Then, methyl iodide was added to the
sample, followed by a second addition of methyl iodide 30 min
later. The permethylated sample was then cooled, and extracted
two times with chloroform:water (1:2, v/v). The organic phase was
dried and then hydrolyzed at 100uC for 6 h with 4 N
trifluoroacetic acid. The sample was then reduced with sodium
borodeuteride and acetylated with pyridine:acetic anhydride (1:1)
at 100uC for 6 h. Samples were then dried under a nitrogen
stream, and the partially methylated alditol acetates (PMAA) were
dissolved in dichloromethane and analyzed by GC-MS.
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Unprocessed capsule was reconstituted in water at a concen-
tration of 3 mg/ml. One ml of the sample was spotted onto a
stainless steel MALDI-MS target, allowed to dry, and overlaid
with 1 ml of a 50 mg/ml solution of 2,5 dihydroxybenzoic acid
(DHB) (Laser Biolabs, Sophia-Antipolis Cedex, France) in 70%
acetonitrile. Samples were subsequently analyzed using an LTQ
linear ion trap mass spectrometer coupled to a vMALDI ion
source (Thermo Fisher). The vMALDI source uses an SI N2 laser
(337.3 nm) with a 20-Hz firing rate. Data was collected in the
positive ion mode using the automated gain control (AGC) and the
automatic spectrum filter (ASF). Tandem mass spectrometry
(MS
n) data were collected using a precursor ion selection window
of 2 m/z and normalized collision energy of 35–40%. Alterna-
tively, samples were analyzed in positive ion mode using the
QStarXL equipped with an oMALDI source (Applied Biosystems,
Foster City, CA).
Mass spectrometric analyses of the capsule for associated
lipids
To test for the presence of lipid A in the capsule, various
preparations of capsule were generated and analyzed by mass
spectrometry. Untreated LPS from F. tularensis strain 1547 was
used for comparison purposes. The capsule was treated with
hydrofluoric acid (HF) for either 2 hours at 20uC or 2 days at 4uC
and subsequently dried down using nitrogen gas, under a vacuum,
over sodium hydroxide. Samples were further processed by
extraction with either CHCl3:CH3OH:H2O (10:5:6) or
CHCl3:CH3OH (1:1), respectively. The organic phases and
precipitate were evaporated to dryness under a nitrogen stream.
Untreated samples were reconstituted in water, spotted onto a
MALDI target, dried, and overlaid with DHB matrix (50 mg/ml
in 70% acetonitrile). Chloroform extracted samples were recon-
stituted in CHCl3:CH3OH (3:1) and overlaid with 6-chloro-3-
mercaptobenzothiazole (CMBT) matrix (saturated solution in
CHCl3:CH3OH (3:1). Samples were analyzed using an LTQ
linear ion trap mass spectrometer coupled to a vMALDI ion
source (Thermo Fisher) operating in the negative ion mode using
the conditions listed above.
NMR methods
An NMR sample was prepared by lyophilizing 4 mg of purified
F. tularensis capsule polysaccharide against 3 changes of D2O and
dissolving the dried material in 0.5 mL of 99.96% D2O from a
freshly broken ampoule. All spectra were acquired at 35uCo na
600 MHz Varian UnityInova NMR spectrometer equipped with
a standard triple resonance probe with pulsed field gradients
except for an HMBC experiment which was acquired on an
800 MHz Bruker Avance II NMR spectrometer equipped with a
TCI cryoprobe. All spectra were processed using NMRPipe
[39,40] and analyzed using Sparky. The following datasets were
used for analysis:
13C-HMQC, gHMBC, gCOSY, DQF-COSY,
TOCSY (20 ms and 60 ms mixing times), and NOESY (200 ms
mixing time). Acquisition and processing parameters are shown in
Table 6.
Ethics Statements. All animals were handled in strict
accordance with good animal practice as defined by the relevant
national and/or local animal welfare bodies, and all animal work
was approved by the University of Iowa Animal Care and Use
committee (ACURF # 0808184). Guidelines provided by the NIH
were followed in all experimentation. The University of Iowa is
PHS assured.
Passive immunization with MAb 11B7 of BALB/c mice
and challenge with F. tularensis LVS
BALB/c female mice 6–8 weeks of age were purchased from
NCI. Two groups of five mice were injected intraperitoneally with
either 75 mg of 11B7 antibody or 75 mg of a matched isotype
monoclonal antibody, 2C3, as a negative control. Antibody 2C3
binds to a Neisseria gonorrhoeae membrane protein, H.8. Both MAbs,
11B7 and 2C3, are IgG1kmonoclonal antibodies. MAb 2C3 was a
gift from Dr. Peter Rice, University of Massachusetts. Both
antibodies were affinity purified over a Protein G (Thermo
Scientific, Rockford, IL) column according to manufacturer’s
instructions. The protein concentration was determined using an
Easy Titer Mouse IgG assay Kit (Thermo Scientific, Rockford,
IL). Twenty four hours post-injection of antibody, both groups of 5
mice were challenged intraperitoneally with 5610
4 cfu (,100
LD50)o fF. tularensis LVS and the ability of the mice to survive
challenge was followed for 14 days. A second experiment was
performed using the same protocol for administration of
monoclonal antibodies but the challenge dose of F. tularensis LVS
was 5610
5 cfu (,1000 LD50).
Challenge of BALB/c mice with F. tularensis LVS
previously immunized with capsule
BALB/c female mice 6–8 weeks of age were purchased from
NCI. Groups of 5 mice were used for each immunization and
challenge protocol. Two groups of five mice were injected
intraperitoneally with 50 ml of phosphate buffer saline (PBS) and
TiterMax Gold adjuvant at a 1:1 ratio. Two separate groups of
mice were immunized intraperitoneally with 10 mg of capsule in a
25 ml volume mixed 1:1 with 25 ml TiterMax Gold adjuvant. Mice
were bled retro-orbitally 30 days post-immunization to test for the
presence of anti-capsule antibodies in the serum. One day post
bleeding each group of mice was given a booster dose of antigen
Table 6. NMR Spectral Parameters.
Experiment F1 SW (Hz) F2 SW (Hz) F1 points, acquired F2 points, acquired F1 points, processed F2 points, processed
1H-13C HMQC 7199.4 12062.7 512* 140* 1024 512
DQF-COSY 5205.6 5205.6 1024* 620* 4096 4096
gCOSY 5205.6 2505.6 2048* 1024 4096 4096
gHMBC 11029.4 38314.2 2048* 700 4096 2048
TOCSY, 20 ms 7199.4 7199.4 1024* 256* 4096 2048
TOCSY, 60 ms 7199.4 7199.4 1024* 256* 4096 2048
NOESY, 200 ms 7199.4 7199.4 512* 256* 2048 2048
doi:10.1371/journal.pone.0011060.t006
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weeks after the boost dose, the mice were bled again and the anti-
capsule antibody was re-assessed. Forty eight hours post-bleeding,
the groups of mice immunized with PBS, were challenged
intraperitoneally with 250 and 750 cfu of F. tularensis LVS. One
group of mice, immunized with 10 mg of capsule in adjuvant, was
challenged intraperitoneally with 5610
4 LVS and the other group
of mice immunized with 10 mg of capsule in adjuvant was
challenged intraperitoneally with 5610
5 cfu of LVS. All mice were
followed for 14 days to determine the ability of the mice to survive
the challenge.
Statistical Analysis. For the challenge experiments, Kaplan-
Meier survival estimates [41] of the survival of each group of mice
were calculated and differences between groups tested using a
log-rank test statistic [41,42]. Survival of all control mice were
compared to survival of all mice treated with MAb 11B7, and
each control group was compared to all immunized mice. All
calculations were done in R (R Development Core Team, 2009)
and the R survival package [43,44].
Supporting Information
Figure S1 Figure S1 shows a Western Blot that demonstrates
that capsule does not appear to be shed during growth into the
supernate of liquid cultures. One microgram of each of the
following underwent SDS-PAGE using a 4–12% gel followed by
transfer to nitrocellulose. Lane 1 contains the molecule weight
controls and the arrow indicates 200 kDa, lane 2 is an organism
pellet loaded into sample buffer, lane 3 is purified LVS capsule,
lane 4, 5 and 6 are 70% ethanol precipitates of 4 (lane 5), 8 (lane 6)
and 24 (lane 7) hour supernates cleared of organisms by
centrifugation at 13,5006g. The bacterial pellets removed from
the 4, 8 and 24 hour supernates are in lanes 8, 9 and 10
respectively. Lane 4 and 11 contained no sample. Lane 12
contains an TX-114 extracted LPS sample. The Western blot was
developed with MAb 11B7 at a dilution of 1;10,000. These studies
show that the majority of the LVS capsule is associated with the
organism and only minimal amounts of capsule are released into
the broth supernate at 24 hours.
Found at: doi:10.1371/journal.pone.0011060.s001 (1.88 MB TIF)
Figure S2 Figure S2 shows the positive-ion MALDI-TOF mass
spectra of unprocessed capsule. The predominant monoisotopic
mass observed is m/z 815, this mass corresponds to the sodiated
form of the 792 Da tetrasaccharide repeating unit. These data
show that we were able to detect up to six repeating units in the
capsule sample.
Found at: doi:10.1371/journal.pone.0011060.s002 (0.21 MB TIF)
Figure S3 Figure S3 shows the positive-ion vMALDI-LIT mass
spectra of HF-treated capsule. After HF treatment, the predom-
inant monoisotopic sodiated masses observed are at m/z 833 and
1625 which corresponds to one or two units of the 792 Da
tetrasaccharide repeat, respectively. The fragments observed after
HF treatment were generated by chemical hydrolysis and
therefore contain an additional water (793+18=811 Da) relative
to the peaks observed in the unprocessed capsule sample that were
generated by gas-phase fragmentation. Masses labeled with an
* designate major masses minus water.
Found at: doi:10.1371/journal.pone.0011060.s003 (0.23 MB TIF)
Figure S4 Figure S4 shows the positive ion-vMALDI-MS
n
analysis of unprocessed capsule. The tetrasaccharide at m/z 793
(A) was sequentially fragmented to yield fragment ions at m/z 606
(B), at m/z 433(C), and at m/z 390 (D). The MS
4 data of m/z 433
demonstrated that it is composed of two carbohydrates monomers
of the same mass, 216 Da, that are adjacent to one another. The
MS
4 data of m/z 390 demonstrated that it is composed of
two carbohydrate monomers with masses of 173 Da and 216 Da
that are located adjacent to one another. Masses labeled with an
* designate major masses +/2 water.
Found at: doi:10.1371/journal.pone.0011060.s004 (0.65 MB TIF)
Figure S5 Figure S5 shows the positive ion-vMALDI-MS
n
analyses of unprocessed capsule. The tetrasaccharide at m/z 793
(A) was sequentially fragmented to yield fragment ions at m/z 577
(B) and at m/z 361 (C). The MS
4 data of m/z 361 demonstrated
that it is composed of two carbohydrate monomers with masses of
173 Da and 187 Da that are located adjacent to one another.
Masses labeled with an * designate major masses +/2 water.
Found at: doi:10.1371/journal.pone.0011060.s005 (0.46 MB TIF)
Figure S6 Figure S6 shows the (A) total ion chromatogram of
alditol acetate (AA) derivatives of F. tularensis capsule. Three
major peaks were observed. One of these peaks could be assigned
to QuiNAc (RT 23.56 min), based on CI (B) and EI (C) data. The
two mass fragments observed in EI mode at m/z 302 and 144 CI
are consistent with the QuiNAc assignment. EI analyses suggested
that the unknown peaks are most likely anhydro-degradation
products of QuiNAc or deformylated Qui4NFm. No peak was
observed that was consistent with HexNAcAN; it has been
previously suggested that this sugar is either too labile or polar to
be observed by these analyses (Y. A. Knirel, et al. Eur. J. Biochem.
1985, 150:541-550). Inositol was spiked in as a control.
Found at: doi:10.1371/journal.pone.0011060.s006 (0.53 MB TIF)
Figure S7 Figure S7 shows (A) the total ion chromatogram of
alditol acetate (AA) derivatives of F. tularensis LPS. QuiNAc,
GlcNAc, GalNAc. Two unknown peaks were detected in these
samples. CI (B) and EI (C) analyses verified the presence of
QuiNAc. The two mass fragments observed in EI mode at m/z
302 and 144 CI are consistent with the QuiNAc assignment. CI
and EI analsyses also suggested that the unknown peaks are most
likely ahydro degradation products of QuiNAc or deformylated
Qui4NFm. Inositol was spiked in as a control.
Found at: doi:10.1371/journal.pone.0011060.s007 (0.64 MB TIF)
Figure S8 Figure S8 shows the total ion chromatogram of
trimethylsilyl (TMS) derivative of the capsule sample (A). QuiNAc
and HexNAcAN were detected in these samples. Fragmentation
analysis verified their identification (B and C, respectively).
Mannitol was included as a control.
Found at: doi:10.1371/journal.pone.0011060.s008 (1.22 MB TIF)
Figure S9 Figure S9 shows the (A) Total ion chromatogram of
TMS derivative of the F. tularensis LPS scanned over a mass range
of m/z 50–600. These data show that the main constituents
observed in this sample include lipid A components as well as core
sugars. (B) Selective ion chromatogram of the LPS sample to scan
for amino sugars. The sample was scanned over the mass range of
m/z 172.5–173.5. These data confirmed the presence of QuiNAc,
GalNAc, and GlcNAc.
Found at: doi:10.1371/journal.pone.0011060.s009 (0.50 MB TIF)
Figure S10 Figure S10 shows the total ion chromatogram of
partially methylated alditol acetate (PMAA) derivatives of F.
tularensis capsule. Data was collected over a mass range of m/z
50–600. QuiNAc with a 3-linkage and a terminal linkage were
identified at 25.40 and 22.57 min, respectively. Fragmentation
analysis verified these assignments (B and C, respectively).
Found at: doi:10.1371/journal.pone.0011060.s010 (0.61 MB TIF)
Table S1 Proposed compositions of masses observed by
MALDI-TOF analyses.
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DOC)
Table S2 High pH-chromatography data from mixture of
standards.
Found at: doi:10.1371/journal.pone.0011060.s012 (0.04 MB
DOC)
Table S3 High pH-chromatography data from F. tularensis
capsule.
Found at: doi:10.1371/journal.pone.0011060.s013 (0.04 MB
DOC)
Table S4 Summary of GC-MS data for TMS derivatives of F.
tularensis capsule.
Found at: doi:10.1371/journal.pone.0011060.s014 (0.03 MB
DOC)
Table S5 Summary of GC-MS data for TMS derivatives of F.
tularensis LPS.
Found at: doi:10.1371/journal.pone.0011060.s015 (0.03 MB
DOC)
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